Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its Alzheimer’s Disease drug candidate (AD drug candidate) UCB0107 with Roche and its subsidiary Genentech. UCB0107 is a monoclonal antibody drug candidate, which is being developed by UCB as a potential therapy for patients with progressive supranuclear palsy […]
Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 billion for the latter’s cancer drug candidate pralsetinib. Through the deal, Roche gains exclusive rights for the co-development and marketing of the investigational drug for RET-altered cancers across the world […]
Roche has signed a licensing deal worth up to $2.85 billion with Sarepta Therapeutics for the exclusive ex-US commercial rights to the latter’s SRP-9001 (AAVrh74.MHCK7.micro-dystrophin), an investigational gene therapy for Duchenne muscular dystrophy (DMD). As per the agreement terms, Sarepta Therapeutics will get an upfront payment made up of $750 million in cash and $400 […]
Roche acquisition of Promedior : Swiss drugmaker Roche has agreed to acquire Massachusetts-based biotech company Promedior in a deal worth up to $1.39 billion, as per the latest pharma acquisition news. The acquisition will give full rights for the Swiss pharma giant to Promedior’s portfolio of molecules targeting serious fibrotic diseases, including PRM-151, which holds […]
US biotech company Convelo Therapeutics has signed an exclusive worldwide collaboration with Roche subsidiary Genentech to fast track discovery and development of novel remyelination drugs for the treatment of multiple sclerosis (MS) and other neurological disorders. Convelo Therapeutics, which is headquartered in Cleveraland, Ohio, is engaged in discovering a new class of drugs that regenerate the […]
California-based healthcare company Clover Health has launched a new research subsidiary, called Clover Therapeutics, which will focus on developing drugs for older adults for the treatment of chronic diseases. Clover Therapeutics has started its journey by signing a research collaboration and license agreement with Roche’s subsidiary Genentech to better understand the genomic factors that increase […]